Tech Company Financing Transactions
PanOptica Funding Round
PanOptica secured a $11 million Series B investment round on 10/10/2017. Backers included SV Health Investors and Third Rock Ventures.
Transaction Overview
Company Name
Announced On
10/10/2017
Transaction Type
Venture Equity
Amount
$11,000,000
Round
Series B
Investors
SV Health Investors (Lutz Giebel)
Third Rock Ventures (Kevin Starr)
Proceeds Purpose
These funds will enable clinical advancement of PAN - 90806, a small molecule anti - vascular endothelial growth factor (anti - VEGF) eye drop for the treatment of neovascular eye diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Morristown Rd. 205
Bernardsville, NJ 07924
USA
Bernardsville, NJ 07924
USA
Phone
Website
Email Address
Overview
PanOptica is a biotechnology company specializing in new treatments for diseases of the eye. The company is looking for differentiable candidates against well-characterized targets with credible clinical/regulatory paths to registration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Chaney
Chief Medical Officer
Martin Wax
VP - Bus. Development
David Bingaman
VP - Finance
Lori Forrest
VP - Operations
Kristine Curtiss
Browse more venture capital transactions:
Prev: 10/10/2017: LifeRaft venture capital transaction
Next: 10/10/2017: Ascendify venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs